IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
Recruiting now · Phase 2
Conditions studied: Breast Cancer, Axillary Nodal Disease, Female Breast Cancer, Axilla; Breast, Mastectomy; Lymphedema, Tumor, Breast
In brief
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.
Key facts
- Study ID
- NCT06092892
- Run by
- Alice Chung
- People needed
- 45
- Starts
- 2024-04-07
- Expected to finish
- 2031-04-01
- Last updated by the study team
- 2026-08-10
Who can join
Age: 45 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Women age ≥ 45
- Clinical T1-2N0 ER+ invasive breast cancer
- US detected biopsy proven axillary nodal disease
- Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
You may not qualify if…
- Palpable nodes on physical exam
- Her2+ or ER- invasive breast cancer
- Extranodal extension > 3 mm on nodal biopsy
- More than 2 suspicious nodes on preoperative imaging
Where it is running
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California, United States (enrolling)
- CS Cancer at Huntington Cancer Center — Pasadena, California, United States (enrolling)
- CS Cancer at Valley Oncology Medical Group — Tarzana, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.